Also, a previous preclinical study suggests that EGFR inhibitors may have different effects on melanoma cells depending on their mutational status, and that EGFR TKI-s especially in combination could be an effective approach to eliminate BRAF-mutant melanoma [43]. This evidence concerns the gene EGFR and melanoma.